Sorafenib is an effective therapy for advanced HCC and affects the PI3K/Akt 22 and JAK-STAT signaling pathways23, hypoxia-inducible pathways 24, epithelial to mesenchymal transition events 25, 26, Mapk14-dependent activation of MEK-ERK 27 , GSK-3β 28 and Atf2 signaling 29, 30. The gene discussed is ATF2; the disease is hepatocellular carcinoma.